Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities.
about
Hepatitis C Virus (HCV)–Specific Immune Responses of Long‐Term Injection Drug Users Frequently Exposed to HCVAlcohol use in opioid agonist treatmentChronic pain and hepatitis C virus infection in opioid dependent injection drug usersHuman immunodeficiency virus-hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in ThailandFactors associated with hepatitis B vaccine series completion in a randomized trial for injection drug users reached through syringe exchange programs in three US citiesPredictors of hepatitis knowledge improvement among methadone maintained clients enrolled in a hepatitis intervention program.Hepatitis C management by addiction medicine physicians: results from a national surveyHepatitis C virus infection is associated with painful symptoms in HIV-infected adults.Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the netherlands.Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults.Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programsThe Massachusetts HIV, hepatitis, addiction services integration (HHASI) experience: responding to the comprehensive needs of individuals with co-occurring risks and conditionsOvercoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.Association between syphilis, antibodies to herpes simplex virus type 2, and recreational drug use and hepatitis B virus infection in the Women's Interagency HIV StudyPharmacologic treatments for opioid dependence: detoxification and maintenance options.CD4 recovery on antiretroviral therapy is associated with decreased progression to liver disease among hepatitis C virus-infected injecting drug usersUtilizing mHealth methods to identify patterns of high risk illicit drug use.Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States.Organizational issues in the implementation of a hospital-based syringe exchange programFrequency of Hepatitis B and C Viruses, and HIV Among Drug Addicts in the Eastern Anatolia, Turkey.Exercise as an adjunct treatment for opiate agonist treatment: review of the current research and implementation strategies.Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug usersComparison of HIV infection risk behaviors among injection drug users from East and West Coast US cities.Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.Economic evaluation of delivering hepatitis B vaccine to injection drug usersThe Prevalence of Hepatitis B and C Among Prisoners in Kahramanmaras, Turkey.The perspectives of injection drug users regarding safer injecting education delivered through a supervised injecting facility.A meta-analysis of the hepatitis C virus distribution in diverse racial/ethnic drug injector groupsDifferences in sociodemographic, drug use and health characteristics between never, former and current injecting, problematic hard-drug users in the NetherlandsMorbidity and mortality profile of human immunodeficiency virus-infected patients with and without hepatitis C co-infection.Hepatitis C virus infection in USA: an estimate of true prevalence.Hepatitis C core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up?Hepatitis C incidence--a comparison between injection and noninjection drug users in New York City.Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection.No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.Effects of buprenorphine on balance of oxidant/antioxidant system in the different ages of male rat liver.Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: results from a 12-month observational study.Exercise as an adjuvant intervention in opiate dependence.Predictors of treatment for hepatitis C virus (HCV) infection in drug users.Injecting shared drugs: an observational study of the process of drug acquisition, preparation, and injection by Puerto Rican drug users.
P2860
Q27488816-7D369AAA-0E18-4475-A681-3F2F04111F60Q28073797-B51B25B1-97B4-408D-AC38-962C977D10E8Q33872397-998377C1-C6E6-4D12-83E7-52C597F2922DQ33915385-9ABA41E5-408B-4F19-A313-895008E77200Q34067472-DBD1567C-E954-46D1-B579-14F63BC0F844Q34079944-808D78CD-0740-41AA-8B5B-8E137FE45ACBQ34090853-88A2833C-E278-4882-A4C3-E3AC0DB63F92Q34137925-92CAD37C-F3E3-41BD-9BEB-CBA883752CCCQ34332039-8B7A87AA-1F0C-4937-9005-69FFE11ADDC6Q34407721-BF688B85-B776-4170-885A-61670B4B65B1Q34735072-86A3981B-2DBD-4BC8-8160-78C132AAAA86Q34770717-DF2EE0A9-BF1C-4DE3-B7F0-C033771A49E0Q34795051-11A77FC5-BBB7-48EE-AB95-A7E9DE4B7C57Q35056693-CA589052-23A9-44C1-B720-A168F3348171Q35454866-8DC06832-B330-4D4D-B4EE-D4AD64D24CA8Q35628281-4A7CF55F-94A6-40EA-9B36-C50370E36C50Q35660947-FF9B479E-9212-4CE8-9E38-63D52B72C010Q35737654-822F2695-5E9F-4CF9-BFFD-90CC91439DACQ36043064-902B78D1-AA80-43DC-8D46-19A2D4388FB6Q36143881-0304D8B5-F593-4104-A940-31885D31E5EDQ36243437-45D33624-002D-4407-8061-55111CD05BF8Q36272770-76C73436-72F3-4778-A6A5-A755229750C0Q36274118-6B23B17F-76F0-46EE-BB0D-F08F9A30CB72Q36421892-FBB4E03F-87FB-433B-A6B7-F4C89D16AE62Q36789998-EBDFCBF3-DF37-4237-AB14-A471E4F0DB69Q36828863-C0582168-870E-4149-ABB7-97CF7C78549AQ37020250-FCFFD2D3-76E3-4027-9D6D-9CFF9E81A2DFQ37031381-A59F0057-F7DC-4C09-AB60-2C795C46FCD8Q37588133-0F6E02A5-B1F2-4A64-9F5D-00F48E03ECD9Q37609379-5D0CF3CF-87BF-4F18-BDCF-A56A66705B79Q37899936-3036E159-DAB9-4BF9-AA6D-6A08AEA73B17Q37961619-94BEF654-8D08-4333-BCD6-CBF8C2A10ECBQ39679908-1665A880-8AF3-4E44-8E17-812CC149CB66Q39918668-8E0995C9-4F1E-4C50-8BF9-B102108CE65EQ40590326-3A7746F1-802B-4858-8910-52DEC6D9865CQ42702559-C5A7B3FD-E93C-4097-AC3C-64AC209CA432Q44347273-32E970D0-678E-4760-8174-749B63493AE6Q44993532-84D9DDE1-8C36-438E-86B3-AB01D02A4D55Q45388321-2284C101-22B3-4D17-91A1-0E25DDC47864Q48487354-5687D152-1FB3-41BA-93F3-D11556D173DB
P2860
Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Age-specific seroprevalence of ...... drug treatment in 6 US cities.
@en
Age-specific seroprevalence of ...... drug treatment in 6 US cities.
@nl
type
label
Age-specific seroprevalence of ...... drug treatment in 6 US cities.
@en
Age-specific seroprevalence of ...... drug treatment in 6 US cities.
@nl
prefLabel
Age-specific seroprevalence of ...... drug treatment in 6 US cities.
@en
Age-specific seroprevalence of ...... drug treatment in 6 US cities.
@nl
P2093
P356
P1476
Age-specific seroprevalence of ...... drug treatment in 6 US cities.
@en
P2093
Beth P Bell
Brian C Castrucci
Catherine Spruill
Christopher S Murrill
Hillard S Weinstock
Howard Weeks
P304
P356
10.2105/AJPH.92.3.385
P407
P50
P577
2002-03-01T00:00:00Z